Cutera (NASDAQ:CUTR) reported quarterly sales of $64.20 million which beat the analyst consensus estimate of $63.42 million by 1.23 percent. This is a 9.58 percent increase over sales of $58.59 million the same period last year.
Finch Therapeutics Announces Clinical Collaboration In Ulcerative Colitis With Brigham And Women’s Hospital And Updates To University Of Minnesota License Agreement
Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome